{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:29:08Z","timestamp":1792085348737,"version":"4.4.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"DOI":"10.1093\/ndt\/gfx072","type":"journal-article","created":{"date-parts":[[2017,3,25]],"date-time":"2017-03-25T08:15:19Z","timestamp":1490429719000},"page":"12-22","source":"Crossref","is-referenced-by-count":26,"title":["Effect of renin\u2013angiotensin\u2013aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"33","author":[{"given":"Ionut","family":"Nistor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"De Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Drechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Tomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Wiecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela-Dora","family":"Donciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bolignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Van Biesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,2]]},"reference":[{"key":"key\n\t\t\t\t20180112014218_gfx072-B1","volume-title":"IDF Diabetes Atlas","year":"2013","edition":"6th edn."},{"key":"key\n\t\t\t\t20180112014218_gfx072-B2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/ki.2010.292","article-title":"National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events","volume":"78","year":"2010","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B3","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/j.1523-1755.2004.00925.x","article-title":"Progression of nephropathy in type 2 diabetic patients","volume":"66","year":"2004","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B4","volume-title":"Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States","author":"U.S. Renal Data System","year":"2009"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ackd.2010.10.003","article-title":"Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management","volume":"18","year":"2011","journal-title":"Adv Chronic Kidney Dis"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B6","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","article-title":"Excess mortality among persons with type 2 diabetes","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B7","first-page":"337","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"@","author":"Kidney Disease: Improving Global Outcomes","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B8","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","article-title":"Standards of medical care in diabetes\u20132014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B9","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"64","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B10","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B11","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B12","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B13","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease","volume":"25","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B14","first-page":"592","article-title":"[Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266\u2009micromol\/L?]","volume":"44","year":"2005","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B15","first-page":"i438","article-title":"Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials","volume":"352","year":"2016","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B16","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B17","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B18","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ndt\/gfv100","article-title":"Guideline Development Group. Clinical practice guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45\u2009mL\/min)","volume":"30","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B19","year":"2009"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B20","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","year":"2004","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.jhh.1000732","article-title":"Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function","volume":"13","year":"1999","journal-title":"J Hum Hypertens"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1291\/hypres.25.865","article-title":"Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy","volume":"25","year":"2002","journal-title":"Hypertens Res"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1463-1326.2005.00514.x","article-title":"The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency","volume":"8","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B24","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1093\/eurheartj\/ehq139","article-title":"Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease","volume":"31","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B27","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/ndt\/gfn770","article-title":"Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan","volume":"24","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B28","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1046\/j.1523-1755.62.s82.13.x","article-title":"Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study","volume":"62","year":"2002","journal-title":"Kidney Int Suppl"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","year":"2003","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B30","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","year":"2005","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/hr.2009.44","article-title":"Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J study","volume":"32","year":"2009","journal-title":"Hypertens Res"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B32","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1007\/s00592-005-0180-4","article-title":"Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study","volume":"42","year":"2005","journal-title":"Acta Diabetol"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B34","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B35","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","year":"2011","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B36","doi-asserted-by":"crossref","first-page":"e1001971","DOI":"10.1371\/journal.pmed.1001971","article-title":"Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses","volume":"13","year":"2016","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.diabres.2011.11.025","article-title":"Effects of renin-angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"96","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B38","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","year":"2004","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B39","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1093\/ndt\/gfq792","article-title":"Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials","volume":"26","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B40","first-page":"CD006257","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease","volume":"4","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","year":"2014","journal-title":"JAMA Intern Med"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","article-title":"Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia","volume":"174","year":"2014","journal-title":"JAMA Intern Med"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B43","first-page":"255","article-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial","volume":"31","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180112014218_gfx072-B44","first-page":"97","article-title":"Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies","volume":"32","year":"2017","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/33\/1\/12\/23439135\/gfx072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T01:42:32Z","timestamp":1515721352000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/33\/1\/12\/3917042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,2]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,7,2]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfx072","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732112391.793544077","asserted-by":"object"}]},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2017,7,2]]}}}